MS brain inflammation study pulled before it started
NCT ID NCT03983252
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This study was designed to see if the drug alemtuzumab reduces activity of certain brain immune cells (microglia) in people with relapsing-remitting multiple sclerosis. Researchers planned to use special PET scans to measure changes over 18 months. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Partners MS Center, 60 Fenwood Road
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.